Kimball Electronics outlines medical CDMO growth strategy in investor presentation
KE•Kimball Electronics expects organic growth in fiscal 2027 as it expands its medical contract development and manufacturing business, with $271 million in short-term liquidity as of September 30, 2026.
1. Medical business expansion
Kimball Electronics expects organic growth in fiscal 2027 as it expands its medical contract development and manufacturing business. The Helvoet Polymer Technologies acquisition is expected to increase earnings and add medical manufacturing capabilities in Europe and India. A new Indianapolis facility doubles the footprint for producing medical products, surgical instruments and drug delivery devices.
2. Capacity and liquidity
The company expects improved capacity utilization to lift margins, supported by a rising share of revenue from medical products. Short-term liquidity totaled $271 million as of September 30, 2026, providing capacity to invest in growth.
